Goldfinch Bio Reports Preliminary Results of GFB-887 in P-II (TRACTION-2) Trial for Focal Segmental Glomerular Sclerosis & Diabetic Nephropathy
Shots:
- The P-II (TRACTION-2) trial evaluates the clinical activity of multiple doses of GFB-887 in 125 patients with FSGS & DN. The results from the pre-specified interim analysis are expected in mid-2022
- The results showed that patients experienced a 32% mean reduction in UPCR @12wks., 9 out of 10 patients (90%) experienced a reduction in UPCR; 4 of 7 patients treated with PBO had an increase in UPCR (57%)
- Patients identified by a novel biomarker showed a 48% PBO adjusted mean reduction in UPCR along with greatest responses while 1 non-responsive patient had a mutation in a tubular gene, no treatment effect in the initial cohort of 44 treated DN patients were observed, was safe & well-tolerated
Ref: Goldfinch Bio | Image: Goldfinch Bio
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
